On October 29, 2024 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, reported that the Company will present at two upcoming scientific conferences (Press release, Sensei Biotherapeutics, OCT 29, 2024, View Source [SID1234647496]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference and Presentation Details:
PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain
Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody
Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer
Session: Antibody-Based Cancer Therapies
Date and time: Tuesday, November 5, 2024, 9:00 a.m. CET (Central European Time)
Society for Immunotherapy Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting, November 6-10, Houston Texas
Title: Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications
Presenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early Development
Presentation Type: Poster
Abstract Number: 70
Date and Time: Saturday, November 9, 2024, 12:15–1:45 p.m. & 7:00-8:30 p.m. CST.
Location: Level 1-Exhibit Halls AB (George R. Brown Convention Center)